Enterprise Value

-38.02M

Cash

142.1M

Avg Qtr Burn

-12.73M

Short % of Float

0.07%

Insider Ownership

3.69%

Institutional Own.

47.85%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Data readout

VTP-300 + AB-729 Details
Chronic hepatitis B

Phase 2a

Data readout

VTP-850 Details
Human papillomavirus, Prostate cancer, Cancer

Phase 1/2

Data readout

VTP-600 Details
Non-small cell lung carcinoma

Phase 1/2

Data readout

VTP-200 Details
Human papillomavirus

Phase 1/2

Update

VTP-1000 Details
Celiac disease

Phase 1

Initiation